康基醫療：2024年度報告.pdf

1、Contents目錄2Chairmans Statement董事長致辭4Corporate Information公司資料7Financial Highlights財務摘要9Management Discussion and Analysis管理層討論與分析30Directors and Senior Management董事及高級管理層42Report of the Directors董事會報告68Corporate Governance Report企業管治報告86Environmental,Social and Governance Report環境、社會及管治報告178Independ

2、ent Auditors Report獨立核數師報告185Consolidated Statement of Profit or Loss and Other Comprehensive Income綜合損益及其他全面收益表187Consolidated Statement of Financial Position綜合財務狀況表189Consolidated Statement of Changes in Equity綜合權益變動表191Consolidated Statement of Cash Flows綜合現金流量表194Notes to Financial Statements財務報

3、表附註297Definition釋義Chairmans Statement董事長致辭Kangji Medical Holdings Limited 2024 Annual Report2Dear Shareholders,Despite the challenges faced in the past year,the Group achieved satisfactory performance growth.During the Reporting Period,Kangji Medical achieved a revenue of RMB1,008.6 million,represen

4、ting a year-on-year increase of approximately 8.9%,primarily attributed to increased sales of disposable products.The profit attributable to owners of the parent company reached RMB581.4 million,representing a year-on-year increase of approximately 15.4%.In 2024,the Group made significant achievemen

5、ts in the nationwide centralized VBP activities for hemostatic tissue ligation clips and won the bidding for a full range of ligation clip products,which laid a solid foundation for the stable development of the Groups business in the future.This nationwide centralized VBP is expected to further pro

6、mote import substitution process,which will be conducive to further increase the market share of the Companys products.The Groups overseas business,benefiting from increased sales in the European market,also maintained a relatively good growth momentum.The Company will continue to allocate resources